Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corticobasal degeneration.

Robert K Mahapatra1, Mark J Edwards, Jonathan M Schott

  • 1Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, UK.

The Lancet. Neurology
|November 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling Protein Aggregate Size Using Single-Molecule Array Technology.

Analytical chemistry·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Plasma proteomic signatures of cellular aging predict human disease.

Nature medicine·2026
Same author

Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Factors influencing implementation of an Alzheimer's disease blood test among UK old age psychiatrists: mixed-methods study using the theoretical domains framework.

Age and ageing·2026
Same author

Plasma proteomics of <i>APOE</i> genotype: age-specific analyses in UK population-based cohorts.

medRxiv : the preprint server for health sciences·2026
Same journal

Resolution of expression of concern-Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.

The Lancet. Neurology·2026
Same journal

UCL Queen Square Institute of Neurology: 75 years of innovation.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 631.

The Lancet. Neurology·2026
Same journal

Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2025; 24: 740-52.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 357-67.

The Lancet. Neurology·2026
See all related articles

Corticobasal degeneration is a progressive brain disorder causing movement and cognitive issues. Definitive diagnosis requires post-mortem examination, though advanced imaging aids clinical identification.

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • Corticobasal degeneration (CBD) is a progressive neurodegenerative disorder.
  • CBD typically manifests as asymmetrical parkinsonism and cognitive impairment.
  • Recent molecular discoveries offer insights into CBD pathogenesis.

Purpose of the Study:

  • To review the diagnostic challenges and current understanding of corticobasal degeneration.
  • To highlight the role of advanced imaging in diagnosing CBD.
  • To discuss the limited treatment options for CBD.

Main Methods:

  • Literature review of recent molecular and imaging advances in corticobasal degeneration.
  • Analysis of clinical presentation variability and differential diagnoses.

Related Experiment Videos

  • Evaluation of current therapeutic strategies.

    • Main Results:

    • Corticobasal degeneration diagnosis is complex due to variable presentations and overlapping syndromes.
    • Advanced neuroimaging techniques show promise in assisting clinical diagnosis.
    • Effective treatments for corticobasal degeneration are currently limited, focusing on symptom management.

    Conclusions:

    • Accurate clinical diagnosis of corticobasal degeneration remains challenging.
    • Post-mortem examination is the only definitive method for diagnosing corticobasal degeneration.
    • Further research into pathogenesis and improved diagnostic tools are needed for corticobasal degeneration management.